Provided by Tiger Trade Technology Pte. Ltd.

Amicus Therapeutics

14.41
-0.0200-0.14%
Post-market: 14.410.00000.00%19:42 EDT
Volume:2.29M
Turnover:32.99M
Market Cap:4.52B
PE:-163.91
High:14.43
Open:14.43
Low:14.41
Close:14.43
52wk High:14.43
52wk Low:5.51
Shares:314.00M
Float Shares:311.00M
Volume Ratio:0.55
T/O Rate:0.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0879
EPS(LYR):-0.0879
ROE:-11.58%
ROA:2.49%
PB:16.50
PE(LYR):-163.91

Loading ...

Nasdaq Surges Over 1%; Lamb Weston Shares Decline Following Q2 Results

Benzinga
·
Dec 20, 2025

Biogen to Acquire Amicus Therapeutics for $4.8 Billion in Rare Disease Bet

Deep News
·
Dec 20, 2025

Top Midday Stories: Oracle, Others Form JV to Oversee TikTok in US; More Drugmakers to Announce US Drug Price Deals

MT Newswires Live
·
Dec 20, 2025

Amicus Therapeutics Inc : Needham Cuts to Hold From Buy

THOMSON REUTERS
·
Dec 19, 2025

Amicus Therapeutics Cut to Neutral From Overweight by Cantor Fitzgerald

Dow Jones
·
Dec 19, 2025

Biomarin Shares Rise 8.9%

THOMSON REUTERS
·
Dec 19, 2025

Amicus Therapeutics Shares Jump 30% Premarket After Biomarin Pharmaceuticals to Acquire Co for $4.8 Bln

THOMSON REUTERS
·
Dec 19, 2025

BioMarin to acquire Amicus Therapeutics for $4.8 Billion

Reuters
·
Dec 19, 2025

Amicus Therapeutics Inc: Pending U.S. Galafold Ip Litigation Resolved

THOMSON REUTERS
·
Dec 19, 2025

Amicus Therapeutics : Deal Substantially Accretive to Non-Gaap Diluted EPS Beginning in 2027 to Biomarin

THOMSON REUTERS
·
Dec 19, 2025

Biomarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook

THOMSON REUTERS
·
Dec 19, 2025

Amicus Therapeutics Inc - Biomarin to Finance Deal With Cash and $3.7 Bln Debt

THOMSON REUTERS
·
Dec 19, 2025

Amicus Therapeutics: Entered License Agreements With Aurobindo & Lupin for Galafold 123 Mg Capsules

THOMSON REUTERS
·
Dec 19, 2025

Amicus Therapeutics: to Grant Aurobindo and Lupin Licenses to Market Generic Versions of Galafold in US From Jan 30, 2037

THOMSON REUTERS
·
Dec 19, 2025

Amicus Therapeutics Shares Halted, Pending Material News Release

MT Newswires Live
·
Dec 19, 2025

NASDAQ TRADE HALT HALT NEWS PENDING AT 07:40 AM

Reuters
·
Dec 19, 2025

Amicus Therapeutics Chief People Officer David Michael Clark Sells Common Shares

Reuters
·
Dec 18, 2025

Amicus Therapeutics Initiated at Buy by Citigroup

Dow Jones
·
Dec 17, 2025

Amicus Therapeutics Inc : Citigroup Initiates Coverage With Buy Rating; Target Price $17

THOMSON REUTERS
·
Dec 17, 2025

U.S. RESEARCH ROUNDUP-Airbnb, Garrett Motion, Range Resources

Reuters
·
Dec 17, 2025